# About Tirzepatide Medicine — Editorial standards and disclosures

> Who runs this site, what it is, and what it is not. An independent editorial chronicle of the tirzepatide evidence base — not a clinic, not a vendor, not a marketing site.

Who we are, how we read the literature, and what we will and won't do on this site.

## What this site is

Tirzepatide Medicine is an independent editorial chronicle of the tirzepatide clinical literature. We summarize, in plain prose, the published evidence on a single FDA-approved peptide medicine — the trials, the mechanism, the dosing, the safety profile. We update the site as new pivotal trials publish.

We model the site on long-form medical journalism: short, declarative summaries; citations to primary sources; no advocacy and no anecdote. Every numerical claim we make traces back to a peer-reviewed paper, a regulatory document, or a registered trial record. The full reference list is on [the references page](/references).

## What this site is not

- **Not a clinic.** We do not diagnose, prescribe, or counsel patients. If you are considering or taking tirzepatide, your prescribing clinician is the relevant authority on your specific situation.
- **Not a vendor.** We do not sell tirzepatide or any other product. We do not link to vendors. We are not affiliated with any pharmaceutical manufacturer, compounding pharmacy, telehealth platform, or supplement company.
- **Not a marketing site.** We are not commissioned by, funded by, or operated on behalf of Eli Lilly and Company or any other drug manufacturer. The trials we summarize were largely sponsored by the manufacturer — we say so each time it is material.
- **Not a personal account.** This site does not host first-person testimonials, before-and-after photos, or user reviews. The evidence base is large enough that anecdote is unnecessary.

## Editorial standards

Three rules govern what appears here:

1. **Every quantitative claim cites a source.** Effect sizes, sample sizes, hazard ratios, doses, half-life — all link to a specific paper.
2. **No medical advice.** We describe what trials measured. We do not recommend what any individual should do with their body.
3. **Brand names are avoided where possible.** Tirzepatide is sold under multiple brand names; we use the generic chemical name, except in two contexts: (a) the page summarizing FDA approvals lists the trade names regulators approved; (b) the references list reproduces titles of papers as published.

We do our own work, on our own schedule, with the expressed goal of being more reliable than a Google snippet and faster to read than a journal abstract. If we get something factually wrong, we will correct it — see [contact](/contact).

---

An independent editorial chronicle of the clinical literature — not a clinic, not a vendor, not a prescription.